Full Press Release Details
REGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM.
REGN
REGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM
Key Takeaway: REGENERON RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR ASPECT OF AXOKINE(R) OBESITY DEVELOPMENT PROGRAM
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism